公开(公告)号：US20250043019A1

公开(公告)日：2025-02-06

申请号：US18811332

申请日：2024-08-21

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  Anna Kuchnio ,  Cassandra L. Lowenstein ,  Ulrike Philippar ,  Sanjaya Singh ,  Nele Vloemans ,  Danlin Yang

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.

公开(公告)号：US20250122299A1

公开(公告)日：2025-04-17

申请号：US18818199

申请日：2024-08-28

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： Gregory L. Moore ,  Michael Hedvat ,  Matthew Adam Dragovich ,  Lorena Fontan Gabas ,  Adam Zwolak ,  Ulrike Philippar ,  Pankaj Seth ,  Nele Vloemans ,  Ivo Cornelissen

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.

公开(公告)号：US20180170909A1

公开(公告)日：2018-06-21

申请号：US15847999

申请日：2017-12-20

Applicant: Janssen Biotech, Inc.

Inventor： Tianbao Lu ,  Brett Douglas Allison ,  Joseph Kent Barbay ,  Peter J. Connolly ,  Maxwell David Cummings ,  Gaston Diels ,  James Patrick Edwards ,  Kevin D. Kreutter ,  Ulrike Philippar ,  Fang Shen ,  Johannes Wilhelmus John Fitzgerald Thuring ,  Tongfei Wu

IPC: C07D401/14 ,  C07D401/12 ,  A61P35/00 ,  A61P19/02 ,  A61P1/00 ,  A61P11/06 ,  A61P37/00

Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.

公开(公告)号：US12103977B2

公开(公告)日：2024-10-01

申请号：US17702282

申请日：2022-03-23

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  Anna Kuchnio ,  Cassandra L. Lowenstein ,  Ulrike Philippar ,  Sanjaya Singh ,  Nele Vloemans ,  Danlin Yang

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C07K16/2878 ,  C07K16/2887 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.